Skip to main content

5 Top Stock Gainers for Tuesday Range Across Sectors Despite Omicron Slump

A shaky market did not put a tamper on these five companies Tuesday.
  • Author:
  • Publish date:

Stocks finished sharply lower Tuesday amid concerns about the omicron variant of Covid-19 and comments by Federal Reserve Chairman Jerome Powell who said it may be time to retire the word "transitory" when it comes to consumer price increases.

Here are some of the top gainers Tuesday:

1. ImmunoGen | Increase  30%

ImmunoGen  (IMGN) - Get Free Report shares soared after the cancer drug specialists said its ovarian cancer treatment met the primary goals of a late-stage study. ImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial.

2. ImmunityBio | Increase 22%

Shares of ImmunityBio  (IBRX) - Get Free Report climbed after EnGeneIC, an Australian biotech, granted the company an exclusive, worldwide license for development through commercialization of its EnGeneIC Dream Vector in combination with its anti-cancer drugs and Covid-19 vaccine. 

3. Navigator Holdings | Increase 14%

Navigator Holdings  (NVGS) - Get Free Report powered higher after the liquefied petroleum gas transporter beat Wall Street's third-quarter earnings and revenue estimates. The company reported earnings of 10 cents a share, beating the Zacks Consensus Estimate of 6 cents a share, and ahead of the year ago figure of 3 cents a share.

4. Identiv | Increase 7.8%

Shares of Identiv  (INVE) - Get Free Report advanced after CVS  (CVS) - Get Free Report said the security technology company will power the pharmacy store operator's Spoken Rx proprietary audio prescription label solution that was developed in collaboration with the American Council of the Blind.

Citi Trends  (CTRN) - Get Free Report shares rose after the fashion apparel retailer beat Wall Street's third-quarter earnings expectations. The company reported quarterly earnings of $1.03 a share, up from 67 cents a year ago and beating the Zacks Consensus Estimate of 48 cents a share.